As illustrated, 60% of placebo patients experienced an improvement from baseline at wk 4 between 1 and 5 points, versus 83% of ARA 290 patients
2 Likes AlexKChen September 8, 2024, 8:19pm #4 Its widely available on various peptide sites now At 32 weeks, patients treated with once-weekly injections of CagriSema had an HbA1c reduction of 2.2% compared with reductions of 1.8% with semaglutide alone and 0.9% with cagrilintide alone, reported Juan Fras, MD, of Velocity Clinical Research in Los Angeles, during the American Diabetes Association (ADA) Scientific Jun 27, 2023 its more expensive than semaglutide though it synergizes
Super happy with my experience
What would change my view A well-designed randomized controlled trial directly comparing at-home microinfusion at 0.5mm with a multi-peptide serum against topical application of the same serum without the device, with VISIA or similar objective imaging at 12 and 24 weeks, would be the cleanest piece of evidence the category currently lacks